Cellectis SA CLLS:NASDAQ

RT Quote | NASDAQ | USD
Last | 06/23/21 EDT
14.80quote price arrow up+0.19 (+1.30%)
Volume
128,606
52 week range
14.18 - 34.71

...

Loading . . .
  • Open14.47
  • Day High14.90
  • Day Low14.47
  • Prev Close14.80
  • 52 Week High34.71
  • 52 Week High Date01/20/21
  • 52 Week Low14.18
  • 52 Week Low Date06/03/21

Key Stats

  • Market Cap672.81M
  • Shares Out45.46M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta2.36
  • YTD % Change-45.31

KEY STATS

  • Open14.47
  • Day High14.90
  • Day Low14.47
  • Prev Close14.80
  • 52 Week High34.71
  • 52 Week High Date01/20/21
  • 52 Week Low14.18
  • 52 Week Low Date06/03/21
  • Market Cap672.81M
  • Shares Out45.46M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta2.36
  • YTD % Change-45.31

RATIOS/PROFITABILITY

  • EPS (TTM)-2.66
  • P/E (TTM)-5.57
  • Fwd P/E (NTM)-5.20
  • EBITDA (MRQ)-108.191M
  • ROE (MRQ)-38.07%
  • Revenue (MRQ)58.52M
  • Gross Margin (MRQ)-207.95%
  • Net Margin (MRQ)-221.19%
  • Debt To Equity (MRQ)41.38%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cellectis SA

There is no recent news for this security.

Profile

MORE
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease...
Jean-Pierre Garnier Ph.D.
Non-Executive Chairman
Andre Choulika Ph.D.
Chief Executive Officer
Eric Dutang
Chief Financial Officer
Jon Voss
Executive Vice President
Address
8, rue de la Croix Jarry
Paris
75013
France

Top Peers

SYMBOLLASTCHG%CHG
EOLS
Evolus Inc
13.96+0.38+2.80%
ANAB
AnaptysBio Inc
24.93+0.25+1.01%
DTIL
Precision BioSciences Inc
10.70+0.06+0.56%
CTMX
CytomX Therapeutics Inc
6.68-0.25-3.61%
GTHX
G1 Therapeutics Inc
21.84+0.48+2.25%